MR accurate in detecting residual disease following lumpectomy

May 07, 2003

Some breast cancer patients who undergo a lumpectomy should then be considered for an MR examination because MR is an accurate way to look for any disease left in the breast, two new studies show. Information on residual disease is vital in determining the best treatment for these women.

In one study, radiologists reviewed 100 patients who had undergone a lumpectomy, whereby the tumor and closely surrounding areas were removed. When the tumor specimen was looked at under a microscope it showed that the cancer had spread to or near the edge (margins) of the specimen.

These women then had an MR examination to look for any residual disease, says Elizabeth Morris, MD, a radiologist at Memorial Sloan Kettering Cancer Center in New York, and lead author of the study. Fifty-eight of the women had disease left over after lumpectomy, says Dr. Morris. Overall, MR imaging identified 86% of residual disease, she says. "It was most accurate (90%) in identifying residual disease that was in a different quadrant than the lumpectomy site; it was least accurate (78%) in identifying unifocal residual disease, that is disease that was within 2 cm of the lumpectomy site," Dr. Morris says.

A separate study of 22 women (23 breasts) with ductal carcinoma in situ confirms Dr. Morris' numbers. In the study, "MR imaging identified residual disease near the lumpectomy site in 18 of the 23 breasts (78%)," says Jennifer Menell, MD, clinical assistant radiologist at Memorial Sloan Kettering Cancer Center.

Nine of the women also had a mammogram, adds Dr. Menell. MR was able to identify residual disease in seven of these nine patients, while mammography was only able to identify residual disease in six patients.

Not all of the patients in this study had positive margins, notes Dr. Menell. Two of the patients had the radiologic examination following lumpectomy to determine the extent of disease.

Two patients had surgery outside of Memorial Sloan Kettering Cancer Center, and information on whether they had positive margins or not wasn't available, says Dr. Menell.

"MR imaging provides us with a window to the breast that we haven't had before and maps out for us how extensive the disease really is," says Dr. Morris. "If tumor extent can be accurately gauged, appropriate treatment can be planned," adds Dr. Menell.

Dr. Menell and Dr. Morris will present their studies on May 7 during the American Roentgen Ray Society Annual Meeting in San Diego.
-end-
Contact:
Keri J. Sperry, 703-858-4306
Danica Laub, 703-858-4332
Press Room: 619-525-6536

American College of Radiology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.